MedTrace Logo

Hypofractionated Radiation Therapy in Prostate Cancer

NCT01764646 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2020-05-19

No results posted yet for this study

Summary

RATIONALE: It is not yet known whether extreme hypofractionation is equally safe and effective than standard radiation therapy in treating prostate cancer.

PURPOSE: This protocol presents a randomised phase II study aiming to investigate the tolerance and disease control of extreme hypofractionated Radiation Therapy for prostate cancer.

Conditions

  • Malignant Neoplasm of Prostate
  • Local Disease

Interventions

RADIATION

Intensity modulated radiation therapy

Minimize radiation doses to surrounding area

RADIATION

Volumetric modulated arc therapy

Highly conformational dose distribution

RADIATION

Image guided radiation therapy

Follow target by the use of fiducial markers and ERB

Sponsors & Collaborators

  • Thomas Zilli

    lead OTHER

Principal Investigators

  • Thomas Zilli, Dr · University Hospital, Geneva

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2020-12-31
Completion
2025-09-30

Countries

  • Belgium
  • Finland
  • Israel
  • Netherlands
  • Portugal
  • Spain
  • Switzerland
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01764646 on ClinicalTrials.gov